Context Therapeutics Inc. cash flow to debt ratio of -23.54K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Context Therapeutics Inc.'s free cash flow has increased -9.87% from $-29.31M last year to $-26.42M, signaling increasing performance

Context Therapeutics Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

Context Therapeutics Inc.'s debt has increased relative to shareholder equity from 0.00 last year to 0.01 today, signaling weakened financials

Context Therapeutics Inc. has a net cash position, so leverage is healthy.

Context Therapeutics Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Context Therapeutics Inc. has insufficient data to evaluate this check.

Context Therapeutics Inc.'s short-term assets of $68.35M exceed its short-term liabilities of $8.02M

Context Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Context Therapeutics Inc.'s return on equity of -82.06%, is lower than 15.00%, indicating bad performance

Context Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Context Therapeutics Inc. has insufficient public price history to evaluate earnings stability.

Context Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Context Therapeutics Inc. has negative free cash flow, indicating cash burn

Context Therapeutics Inc.'s yearly earnings has decreased 35.17% since last year from $-26.73M to $-36.12M, signaling decreasing performance

Context Therapeutics Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -126.84% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Context Therapeutics Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Context Therapeutics Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Context Therapeutics Inc. has insufficient public price history to evaluate ROE consistency.

Context Therapeutics Inc. is overvalued relative to its fair value price of 0.38 based on Discounted Cash Flow model

Context Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Context Therapeutics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Context Therapeutics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Context Therapeutics Inc. has insufficient data to evaluate this check.

Context Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Context Therapeutics Inc. has a price-to-book ratio of 1.13x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Context Therapeutics Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue